<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620710</url>
  </required_header>
  <id_info>
    <org_study_id>PRIAMOS</org_study_id>
    <nct_id>NCT01620710</nct_id>
  </id_info>
  <brief_title>Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes</brief_title>
  <acronym>PRIAMOS</acronym>
  <official_title>Hypofractionated Helical Intensity-Modulated Radiotherapy of the Prostate Bed After Prostatectomy With or Without the Pelvic Lymph Nodes - the PRIAMOS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates safety and feasibility of a hypofractionated radiotherapy (i.e. with
      higher daily doses and shorter total treatment time compared to standard fractionation) of
      the prostate bed with or without the pelvic lymph nodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While evidence on safety and efficacy of primary hypofractionated radiotherapy in prostate
      cancer is accumulating, data on postoperative hypofractionated treatment of the prostate bed
      and of the pelvic lymph nodes is still scarce. This phase II trial was initiated to
      investigate safety and feasibility of hypofractionated treatment of the prostate bed alone or
      with the pelvic lymph nodes.

      A total of 80 prostate cancer patients with the indication for adjuvant radiotherapy will be
      enrolled, where 40 patients with a low risk of lymph node involvement (arm 1) and another 40
      patients with a high risk of lymph node involvement (arm 2) will each receive 54 Gy in 18
      fractions to the prostate bed. Arm 2 will be given 45 Gy to the pelvic lymph nodes
      additionally. Helical Tomotherapy and daily image guidance wil be used.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion SDR of patients with no grade III/IV toxicity and/or treatment discontinuation</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion SDR of patients with no NCI CTC AE grade 3-4 toxicity and no discontinuation of treatment during the full set of 18 fractions by any reasons in the intent-to-treat (ITT) population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>biochemical recurrence free survival (BFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of Life Scores as measured by the EORTC-QLQ30 and -PR25 questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>prostate bed</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)
This arm has already finished recruitment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prostate bed &amp; lymph nodes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated helical IMRT</intervention_name>
    <description>hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy</description>
    <arm_group_label>prostate bed</arm_group_label>
    <arm_group_label>prostate bed &amp; lymph nodes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated helical IMRT</intervention_name>
    <description>helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)</description>
    <arm_group_label>prostate bed</arm_group_label>
    <arm_group_label>prostate bed &amp; lymph nodes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resected prostate carcinoma with histological grading (Gleason Score)

          -  status post prostatectomy for a pT3 carcinoma and/or R1/2 resection or PSA recurrence
             after prostatectomy (2 consecutive PSA rises)

          -  PSA recurrence ≥ 1 ng/ml: CT/PET/MRI imaging excluding pathological lymph nodes

          -  Karnofksy performance score ≥ 70 %

          -  age 18 - 80 years

          -  only arm 2: antihormonal therapy for 2 months prior to radiotherapy and continuation
             of hormonal suppression after radiotherapy recommended

          -  written informed consent

        Exclusion Criteria:

          -  patient's refusal

          -  patient's inabillity to give informed consent

          -  stage IV (distant metastases)

          -  lymph node involvement outside the pelvis

          -  severe wound complications after laparatomy

          -  only arm 2: severe lymphoedema of the legs, elephantiasis, postthrombotic syndrome

          -  decompensated pulmonary, cardiovascular, metabolic, hematopoetic, coagulatory or renal
             comorbidities

          -  known other malignant disease with distant metastases

          -  prior pelvic irradiation

          -  participation in another clinical trial that might compromise the results of the
             PRIAMOS trial or the other trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Herfarth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Radiation Oncology, University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Katayama S, Striecker T, Kessel K, Sterzing F, Habl G, Edler L, Debus J, Herfarth K. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):926-33. doi: 10.1016/j.ijrobp.2014.07.015. Epub 2014 Sep 9.</citation>
    <PMID>25216858</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth, MD</investigator_full_name>
    <investigator_title>Principal Inverstigator</investigator_title>
  </responsible_party>
  <keyword>prostatectomy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

